CEL-SCI Corp. (CVM), a clinical stage cancer immunotherapy company, announced the pricing of a public offering of about 1.11 million shares of its common stock at $9.00 per share.
Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $10 million.
The offering is expected to close on August 29, 2025.
The company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate purposes, and working capital.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.